Allergen molecules (synonyms: single allergens, allergen components) open up new horizons for the targeted allergen-speci c diagnostics of immunoglobulin E (IgE) in singleplex determination. e following rationales support the targeted use of allergen molecules and, more importantly, improve test properties: (1) increased test sensitivity ("analytical sensitivity"), particularly when important allergens are under-represented or lacking in the extract; (2) improved test selectivity (analytical speci city), particularly when the selected IgE repertoire against an allergen yields additional information on: (a) potential risk, (b) possible cross-reactivity, or (c) primary (species-speci c) sensitization. However, the appropriate indication for the use of single allergens can only be established on a case-by-case basis (depending on the clinical context and previous history) and in an allergen-speci c manner (depending on the allergen source and the single allergens available), rather than in a standardized way. Numerous investigations on suspected food allergy, insect venom allergy, or sensitization to respiratory allergens have meanwhile demonstrated the successful use of de ned molecules for allergen-speci c singleplex IgE diagnosis. Speci c IgE to single allergens is limited in its suitability to predict the clinical relevance of sensitivity on an individual basis. In food allergies, one can at best identify the relative risk of a clinical reaction on the basis of an IgE pro le, but no absolutely reliable prediction on (future) tolerance can be made. Ultimately, the clinical relevance of all IgE ndings depends on the presence of corresponding symptoms and can only be assessed on an individual basis (previous history, symptom log, and provocation testing with the relevant allergen source where appropriate). us, also in molecular allergology, the treating physician and not the test result should determine the clinical relevance of diagnostic ndings.
Introduction
Atopy is a genetic predisposition to develop class E antibodies, immunoglobulin E (IgE), against harmless, common environmental allergens.
Recent epidemiological studies showed that 46.5 % of the adolescent and 48.6 % of the adult population in Germany have speci c IgE to at least one of the tested allergen sources (pollen, mites, animal dander, molds, food).
Diagnostic tests that either directly or indirectly detect IgE in the context of an increased susceptibility to allergies (sensitization) are referred to as sensitization tests. In the presence of allergy symptoms that are consistent with IgE sensitization, one speaks of a clinically relevant allergy.
IgE, IgE receptors, and the e ector phase of allergic reactions: background information and relevance in IgE diagnostics
As the least abundant human antibody, IgE was not discovered until 1966 (see [3] for an historical summary). Approximately half of IgE is found as free IgE in the vascular bed, while the other half is bound by the IgE receptors of a variety of cells. e high-a nity IgE receptor (FcεRI) on tissue-bound mast cells and basophils is the most important binding partner (approximately 100,000-250,000 FcεRI/ basophilic leukocyte; Fig. 1 ) in immediate-type allergic reactions. Although free serum IgE has a halflife of only a few days, FcεRI-bound IgE persists for approximately 2 months due to a slow o -rate. us, it is not free but rather cell-bound IgE that is essential for the e ector phase of the allergic reaction. Upon re-exposure to allergens speci c IgE antibodies are cross-linked, either in pairs or as large aggregates. It takes on average 2000 cross-linked IgE molecules to induce a half-maximal cell response (e.g., histamine release, Fig. 1 ), i.e., only a fraction of total cell-bound IgE (200,000 molecules/basophil, range 100,000-250,000). For this reason, basophil tests have an extremely high test sensitivity. e activation status of e ector cells can be quanti ed by the expression of speci c surface markers (CD63, CD203c) using ow cytometry; basophilic leukocytes from fresh blood are generally used here, since they are easier to isolate (basophil activation test, BAT).
e following variables have a signi cant e ect on the dose-dependent activation of basophilic leukocytes [4] : -e total amount of cell-bound IgE -e ratio of speci c IgE to total IgE (as little as 1 % is su cient for half-maximal activation of e ector cells, see above) -e number of epitope-speci c antibodies capable of binding (clonality) -e binding strength between individual IgE antibodies and the allergen (a nity) -e total number of multivalent speci c IgE binding sites that bind strongly to the allergen (avidity) -e ratio of low-to high-a nity IgE antibodies IgE stabilizes the continuously newly synthesized FcεRI receptors at the cell surface [5] . In this way, the level of total IgE passively regulates the number of its receptors and thus also the amount of cell-bound IgE [6] . e complex variables involved [7] , besides the allergen-speci c IgE level, explain why various sensitization tests (speci c IgE, titrated skin test, dose-dependent BAT) correspond well qualitatively (correspondence between positive or negative results) but not quantitatively [8] . more alike and abundant the common binding sites ( epitopes), the likelier it is that speci c IgE will bind to allergens of similar structure-the basis of serological or clinical cross-reactivity. Polyclonal IgE antibodies di er in terms of their binding strength (avidity/a nity) and recognition of speci c epitopes [9] . e resulting IgE repertoire, e.g., against one allergen molecule, is therefore made up of a multitude of antibodies with di ering epitope speci city and binding strength. In the course of the immune response to an allergen, the repertoire can expand and the binding strength increase through the recognition of further epitopes. To date, it has only been possible to investigate the variables described (epitope speci city, avidity, polyclonality) under experimental conditions, not in routine tests. us, even modern quantitative singleplex tests for speci c IgE determination using individual allergen molecules can recognize only the total quantity of the polyclonal IgE response ("the scale of the iceberg") in the best case, while additional parameters of the allergen-speci c repertoire ("the number and height of the various tips of the iceberg") continue to remain hidden to routine diagnostics [10] . As such, they are comparable in terms of the diagnostic (qualitative) information they yield, even though there can be signi cant quantitative variation between results, particularly in the case of di erent allergen sources and due to the variables mentioned above [8] .
Techniques to detect sensitization in routine diagnostics

Technological basis of IgE determination
Solid phase immunoassays for the routine diagnosis of speci c IgE have been available since the early 1970s. Initially, radio-immunological methods (radioallergosorbent test, RAST) consisted of immobilized allergen extracts to activated paper disks in order to bind speci c IgE from the sera of allergy sufferers. Today, assay signals are no longer detected by means of a radioactive label, but rather by means of enzyme labeling or uorometry; moreover, molecules are also increasingly used in this context. Since there are no internationally accepted calibration standards for allergen-speci c IgE tests, a total IgE calibration curve is used to convert the units measured to be expressed as quantitative allergen-speci c IgE antibody levels ( Fig. 2) : kU A /l (where "A" stands for "allergen-speci c", thereby distinguishing units from the internationally standardized kU/l=IU/ml for total IgE determination). To this end, a reference curve calibrated to the ofcial WHO standard for total IgE (formerly WHO 75/502, currently WHO 11/234) is generated following each assay run according to the speci cations of the manufacturers of these diagnostic products. e measurement signals thus obtained for allergen-speci c IgE are then converted into the corresponding units (kU A /l) with the help of this total IgE reference curve ("heterologous" calibration). As part of this process, one assumes a comparable binding strength between the allergen (extract) and speci c IgE or between the primary anti-IgE antibodies used for the reference curve and total IgE-a source of error to a certain extent, which nevertheless needs to be accepted for heterologous calibration and which can cause deviations of maximum 10 %. e randomly assigned "classes" that have evolved over time serve to semi-quantitatively and broadly categorize IgE concentrations and, in the authors' view, play only a minor role today. e test systems currently avail able, as well as their test principles, are listed in Tab. 1.
Test design and test components
Detection thresholds in sIgE determination
e lower detection threshold for speci c IgE was formerly 0.35 kU A /l. e sensitivity of IgE test methods is now higher thanks to more sensitive calibration and improved resolution of low IgE values. us, modern speci c IgE immunoassays now yield values below 0.35 down to 0.1 kU A /l (Fig. 2) . is range is particularly informative and relevant when total IgE is extremely low (<20, <10, <5 kU/l). e upper detection limit is 100 kU A /l for most speci c-IgE detection methods. erefore, sera with higher speci c IgE should be measured in diluted form (1:10) in order to determine the actual value a er multiplying ×10.
Speci c IgE/total IgE ratio
Certain modern assays have shown that the unit for total IgE (kU/l) corresponds to the heterologously calibrated units for allergen-speci c IgE (kU A /l) [15] . Working on this assumption, both variables, speci c and total IgE, can be directly compared and used to improve interpretation [16] . e ratio of speci c IgE to total IgE (also referred to as antibody-speci c activity [16] ) is particularly important in the case of: -Extremely low total IgE levels (e.g., <20 kU/l, <10 kU/l, < 5 kU/l): -For instance, in some atopic patients with unusually low total IgE -Non-atopic patients with IgE sensitization to particular allergens, e.g., insect venom or occupational allergens -Extremely high total IgE levels:
-For instance, in atopic patients with currently or previously manifest atopic dermatitis -In patients with other causes of extremely high total IgE [12] It is important to bear in mind that normal distribution of IgE is not linear, but rather logarithmic and needs to be represented using logarithmic scales (Fig. 2) .
e ratio of speci c IgE to total IgE in serum is found in the same way on e ector cells (mast cells, basophils). If speci c IgE is given relative (e.g., in , this term is no longer provided for; speci c IgE levels given only in classes are considered as qualitative evaluations); C qualitative. Allergen-speci c IgE levels expressed as units of speci c IgE, kU A /l (A stands for allergen-specic), using WHO standards for total IgE determination (heterologous calibration). Light gray area: population of serum samples with no allergen-speci c IgE (levels fall below the detection limit of 0.1 kU A /l). Dark gray area: population of positive serum samples with logarithmic (hypothetically normal) distribution of allergen-speci c IgE levels above the detection limit of 0.1 kU A /l percent) to total IgE (see Fig. 3 for a more detailed explanation) [16] , the values relating to individual total IgE levels are normalized: by taking this step, one can expect better concordance between the relative speci c IgE proportion (in percent) and the quantitative analysis of other sensitization tests (skin prick test, BAT).
Isoforms: natural variants of allergen molecules
Points of criticism on use of allergen molecules relate to their origin or production:
When derived from natural sources, even de ned allergens are variable mixtures with multiple molecule variants (isoforms), which bind IgE with varying strength depending on the individual IgE repertoire. Mixing isoforms potentially has the advantage of covering all IgE speci cities; however, complex mixtures of this kind are challenging to purify and standardize. erefore, allergens molecules are predominantly used in recombinant form for molecular IgE diagnostics.
Possible applications for allergen molecules in IgE diagnostics
Serological in vitro diagnosis can be modi ed in di erent of ways using single allergens: a. Allergen molecules are used individually as reagents for speci c IgE determination (currently the most frequent application). b. Selected allergens are combined as reagents for speci c IgE determination (combination of im- 
De nition of terms used to measure test method e cacy
Analytical sensitivity is de ned as the slope of an (immuno)assay's calibration curve. The actual sensitivity (lower detection limit) of a test, on the other hand, is determined and expressed today using the following variables [19] :
LoB: LoB is de ned as the highest apparent test signal obtained from repeated blank measurements (serum sample without IgE): LoB = meanblank + 1.645 (SDblank).
LoD: LoD refers to the weakest signal or lowest concentration of speci c IgE antibodies reliably determined from the test: LoD = LoB + 1.645 (SDlow concentration sample).
LoQ:
LoQ is the lowest concentration of speci c IgE antibodies that can be reliably detected within a prede ned precision. LoQ may be equivalent to or higher than LoD. is procedure has also known as component-speci c or component-resolved diagnostics (CRD) [17] and currently plays the largest role in molecular allergy diagnostics (typical case studies in [18] ). A selection of the single allergens currently available for IgE determination using singleplex assays and their signi cance in routine diagnostics has been summarized in a separate table (Tab. S1) and is available as an online supplement under http://link.springer.com/journal/40629 .
Distinction between puri ed and recombinantly produced components
An important crossroad for the manufacturers of diagnostic products is the decision whether to use puri ed natural single allergens with all their variants (isoforms) or whether to select a single, recombinantly produced protein. e latter should be representative and have the major IgE binding sites in order to be able cover, as far as possible, all allergy su erers sensitized to this allergen molecule. is problem does not apply when natural components are used, since these generally contain all molecule variants occurring in natural allergen sources. It is only important to ensure here that the preparations do not contain any impurities with other allergens. is is particularly challenging if the allergen to be puri ed is available in very small quantities in the allergen source, while other allergens are present in high concentrations. A typical example would be allergens in bee venom (Api m 3, Api m 5, Api m 10), which are present at less than 1% of the venom dry weight, while Api m 4 (melittin), with more than 40 % of the venom dry weight, render clean puri cation of the above-mentioned allergens virtually impossible.
Another problem with puri ed natural allergens is encountered when glycoproteins with N-glycan sugar side chains are involved, which are recognized as cross-reactive carbohydrate determinants (CCD) by CCD-speci c IgE, thereby falsifying results.
In contrast to the puri cation of allergens from natural sources, the recombinant production of allergens by selecting the appropriate expression system enables one to circumvent the problem of CCDs.
us, expressing allergens in Escherichia coli bacteria permits their production without CCD, while production in yeast cells or certain insect cells makes allergens with normal or modi ed carbohydrate side chains possible.
Technical laboratory evaluation: test sensitivity and analytical speci city (selectivity)
Test method e cacy is investigated on an international basis using the variables sensitivity and spec- Fig. 3 : Signi cance of the total and speci c immunoglobulin E (IgE) ratio. Due to the variability of total IgE levels, logarithmically distributed speci c IgE (dark gray bars) can also be expressed as a relative quantity of total IgE (light gray bars) [16] . This process "normalizes" speci c IgE to total IgE on a percentage basis (hat-hat-hat ched bars). Primarily the borderline cases (see numerical examples) with particularly low (normal distribution curve, far left) or extremely high total IgE (normal distribution curve, far right) make it clear that speci c IgE can only be correctly interpreted once total IgE is known. This ratio of speci c to total IgE is also found on the surface of e ector cells (mast cells, basophil granulocytes), thereby providing the basis for diagnostic ex vivo (basophil activation test, BAT) and in vivo tests (skin prick test, provocation test) i city. As part of this process, a distinction is made between two pairs of de nitions: analytical and diagnostic sensitivity and sensitivity and sensitivity speci city. ese de nitions are also being introduced in international laboratory guidelines for IgE determination methods and are particularly important when single allergens are used.
Test sensitivity is o en improved (i.e., LoQ is low Test sensitivity is o en improved (i.e., LoQ is low Test sensitivity -er) when using allergen molecules, particularly if these allergens are under-represented in the natural extract or are entirely absent due to their instability. Greater test sensitivity (lower LoQ) is thus an important argument in support of the use of allergen molecules for the diagnosis of speci c IgE (Fig. 4;  Tab. 2).
Example
Sensitization to wheat extract is found in only 20 %-30 % of patients with wheat-dependent exercise-induced anaphylaxis (WDEIA), while sIgE to Tri a 19 (Ω-5 gliadin) is detected in 80 %-90 % of cases. Since the gliadins responsible for WDEIA are not water-soluble, they are not present in su cient quantities in aqueous wheat extracts. is problem can be avoided by using a recombinantly produced Tri a 19 in the test system. e analytical speci city of an IgE test method can analytical speci city of an IgE test method can analytical speci city relate to the speci city of the antibody class on the one hand, whereby the test truly determines IgE and no antibodies of other classes, such as IgA, IgD, IgG or IgM [14] .
On the other hand, analytical speci city can relate to a more targeted, more "selective" IgE determination of particular allergen molecules: whereas an allergen extract, as a complex protein mixture, determines the total IgE repertoire to an allergen source, only a proportion of speci c antibodies are determined when using allergen molecules, thereby increasing analytical speci city (selectivity).
is permits more targeted (more analytically speci c) detection or exclusion of sensitization particularly in the case of allergen molecules with special characteristics-such as high stability and a relatively high proportion of total protein (e.g., Ara h 2 or Cor a 14) and thus an increased risk for severe reactions to food (peanut or hazelnut).
More than 10 % of German children and adolescents show speci c IgE to peanut extract-caused primarily by pollen-associated cross-reactions. Diagnosis using the stable and risk-related peanut storage protein, Ara h 2, yields elevated values in only a fraction of patients (circa maximum 0.4 %), thereby providing greater analytical speci city (selectivity) than peanut extract.
Universal arguments for the use of molecular allergens in IgE diagnostics
Four arguments generally provide plausible support for the use of single allergens (Fig. 4) . In this context, particularly the improved test sensitivity (LoQ) and the increased analytical speci city mentioned above help to justify the use of allergen molecules (Fig. 4 and examples a The benefit of allergen molecules as diagnostic reagents from different allergen sources/extracts (left column), the rationales, and potentially improved test characteristics (top line) vary and depend on the individual diagnostic question and the specific allergen used. b Profilin family members: widespread, highly conserved, and extremely cross-reactive panallergens in pollen and plant-based foods. c Polcalcin family members (pollen Ca ++ -binding proteins): widespread, highly conserved, and extremely cross-reactive panallergens in pollen.
a ected individuals with potential cross-reactions). 4. Depending on ndings, particular allergen molecules are suitable as protein-family or speciesspeci c IgE-binding marker allergens to detect or exclude genuine ("primary") sensitization. It should be noted here that all the above-mentioned arguments move primarily on the level of sensitization and do not take the clinical status of the patient into consideration.
Clinical evaluation: diagnostic sensitivity and speci city
Diagnostic sensitivity and speci city relate to the symptoms of the a ected allergy su erer. A precondition to assessing and calculating these is: unequivocal clinical information from the patient or, in case of doubt, additional provocation tests to con rm the clinical diagnosis ( Table 3 , right column). However, allergen-speci c IgE diagnostics only cover sensitization (susceptibility to allergy) and cannot per se predict the clinical reaction [12, 14] .
erefore, concordant results (positive history and positive speci c IgE), for instance, are o en referred to as clinically relevant (instead of correctly positive).
e same applies to concordant negative results that exclude allergy, and thereby also an underlying sensitization. A positive IgE nding combined with a negative history is o en classi ed as clinically irrelevant (instead of false positive). Declaring clinically irrelevant results as false positive does not go to the core of the matter, since ultimately the test result, i.e., the allergen-speci c IgE that is present, can very well be valid and should not be questioned in the rst place. A number of clinical studies have investigated the diagnostic sensitivity and speci city of individual allergens from one allergen source. By increasing test sensitivity (low LoQ), absent or under-represented allergens were also able to signi cantly increase diagnostic sensitivity. However, increased sensitizations were reported parallel to this, even in individuals with no clinically relevant reactions.
e interdependence between diagnostic sensitivity and speci city is a fundamental problem in testing and is o en presented in receiver operating characteristic (ROC) curves. Better diagnostic sensitivity and speci city for the risk assessment of severe clinical reactions has been described for some single allergens, such as Ara h 2 or other highrisk allergens from the 2S-albumin group of storage proteins (overview in [20] ). Moreover, predictive speci c IgE decision points for positive or negative oral provocation in children with suspected peanut or hazelnut allergy have been de ned with the help of risk-related 2S albumins [21] .
It must be borne in mind in relation to these complex clinical investigations that a clinical reaction (or absence thereof) can never be predicted in a foolproof manner (to 100 %) using sensitization tests such as IgE determination [21] . erefore, methodological arguments rst need to be considered for future assessments of the diagnostic suitability of allergen molecules (Tab. 3, le column). Even without a complete clinical evaluation (including diagnostic sensitivity and speci city, as well as predictive values; Tab. 3, right column) the analytical test characteristics of IgE diagnostics using allergen molecules is, in many cases, signi cantly better compared with allergen extracts [22] . is viewpoint is re ected in updated international laboratory guidelines on IgE test methods [14] and should serve to ease and accelerate the evaluation and introduction of allergen molecules for diagnostic purposes in the future.
Interpretation to establish clinical relevance
Ultimately, the central question relates to the clinical relevance of the speci c IgE concentrations obtained: -e following basic rule still applies: a nding of positive speci c IgE is consistent with a sensitization that is only clinically relevant in the presence of corresponding symptoms. -A negative speci c IgE nding (e.g., to an allergen molecule or a mixture of natural isoforms of a single allergen) largely excludes allergic sensitization to the tested allergen; however, only if: -Total IgE is su ciently high -e allergen is available intact and in adequate quantities -e analytical test sensitivity of the IgE determination method has been optimized and is su ciently high Finally, irrespective of whether allergen extracts or molecules are used for diagnostic purposes, only a physician can determine the clinical relevance of an allergic sensitization, not the test.
erefore, all diagnostic ndings from sensitization tests-and that applies equally to allergen molecules-need to be evaluated in the clinical context and on the basis of the individual patient's previous history.
Potentials and quantitative concepts of molecular allergology
Diagnostic methods using single allergens provide new opportunities to di erentiate the IgE response to certain allergen sources. Some marker allergens are characteristic of certain allergen sources and enable their unequivocal classi cation. ese triggers of genuine, primary sensitization are also referred to as species-speci c allergens and can be used as "markers" for certain allergen sources. us, in this Allergo J Int 2015; 24: 185-97 part of the world for example, it is possible to reliably detect sensitizations to pollen using marker allergens and to exclude potential cross-reactions.
is is particularly useful in the case of additional sensitizations to panallergens from the polcalcin and pro lin families, in order to re-establish the analytical speci city of exclusively extract-based diagnosis that is otherwise inadequate in this setting. Polcalcins and pro lins are present in a wide variety of allergen sources and, due to their high structural similarity, are responsible for marked cross-reactions. Although rarely of clinical relevance, they complicate speci c diagnosis when extracts alone are used, since the latter contain both marker and cross reactive allergens.
As part of test interpretation, primary sensitization in the case of a series of positive IgE results can be deduced from in the level of IgE concentrations: e primary sensitizing allergen has the most epitopes recognized by speci c IgE antibodies. In contrast, the number of cross-reactive epitopes of structurally related, similar protein allergens is o en lower and/or the epitopes of lower a nity.
e following rule of thumb applies: e highest IgE level to a protein compared with other members of the same protein family likely reveals the primary sensitizer.
The use of singleplex IgE tests in Bet v 1-related cross-reactivity
A classic example of this is the PR-10 protein family, in the case of which primary birch pollen sensitization is evidenced by high Bet v 1-speci c IgE levels, while Bet v 1-related secondary pollen or food sensitizations are re ected in low IgE values to the relevant Bet v 1-homologous PR-10 proteins (Fig. 5b) . Moreover, the structural relationship between allergens in a family can be indirectly ascertained from the level of speci c IgE (Fig. 5b) .
The use of singleplex IgE tests in pro lin sensitization
In the case of strong structural similarity and marked cross-reactivity within an allergen family, one can expect comparable speci c IgE levels to the individual proteins, as observed with pro lins for example (Fig. 5c) . Determining IgE to pro lins from di erent allergen sources is unlikely to bring any bene t here. A single IgE measurement, e.g., to grass pollen pro lin Phl p 12 or birch pollen pro lin Bet v 2, is su cient. It is possible to establish the clinical relevance of IgE sensitization by means of detailed patient interviews: e.g., potential symptoms induced by botanically unrelated pollen plants or reactions to plant-based foods that, in particular, do not belong to the Bet-v-1 cluster, e.g., melon, banana, exotic and citrus fruits [23] .
The use of singleplex IgE tests against storage proteins IgE levels against members of the same protein family can vary signi cantly in the case of low structural similarity and correspondingly low cross-reactiv- ity, as can be seen with the example of storage proteins (Fig. 5a) .
Although the typical basic structure of storage proteins, i.e.,: -2S albumins -7S globulins -11S globulins from di erent allergen sources-such as legumes (peanut, soybean), tree nuts (hazel and walnut), and seeds-is similar, only partially cross-reactive, potential IgE-binding epitopes are present. As a result, a complex pattern of possible cross-reactivities emerges, depending on the individual IgE repertoire. e IgE response to one storage protein (e.g., Ara h 3 from peanut) does not permit an assessment of IgE reactivity to other members of the 11S globulin family (e.g., Gly m 6 from soybean or Cor a 9 from hazelnut). us, strictly speaking, the sensitization pattern to storage proteins can only be determined by using all available proteins from this storage protein family. Unfortunately, not all members of these stable allergens from tree nuts, capsule and stone fruits, as well as seeds are as yet available, meaning that gaps remain in our diagnostic potential for the time being.
As a result, the highest IgE level to a particular storage protein (e.g., Ara h 2 from the 2S albumin group) likely reveals the primary source of sensitization (e.g., peanut). Lower levels, e.g., to corresponding soy (2S albumin Gly m 8) or hazel nut allergens (2S albumin Cor a 14) signal potential IgE cross-reactivity. However, their clinical relevance and the associated risk of reactions following consumption of the respective allergen source cannot be established from the level of speci c IgE, but needs instead to be conclusively established by the patient's history or challenge tests.
Higher than expected IgE levels (to a food protein investigated as a secondary allergen source) raise doubts about the suspected primary allergen source and should be carefully investigated for plausibility.
Only when the corresponding proteins from the same protein family yield wholly negative IgE values can one assume that serological cross-reactivity is absent and that no clinical (cross-) reactions are to be expected.
us, a negative result is particularly important for the exclusion of an allergic (cross-) reaction.
It is here that the current limitations of molecular allergy diagnostics become apparent, since a structural relationship between allergens, depending on individual IgE repertoires, can determine highly variable cross-reactivities: from completely absent to strong IgE binding of similar epitopes. e various serological and clinical reaction patterns are ultimately based on numerous variables that go beyond the purely structural characteristics of the allergens:
-Personal IgE repertoires with individual patterns of serological and potential clinical cross-reactions -Proportion of the allergen relative to the total protein or total weight -Stability of the relevant allergens, which depends on the processing of the food -Volume of the food consumed -Co-factors for a systemic or anaphylactic reaction. Against the background of these factors, e orts to make successful clinical predictions on the basis of molecule-speci c IgE sensitizations are limited in their scope. It is essential, therefore, to correct disproportionate expectations of molecular diagnostics. IgE sensitization tests can be optimized using de ned allergens and plausible criteria (predominantly independently of the clinical phenotype).
e advantages for serological diagnosis, however, have to be demonstrated for each allergen separately.
Conclusions for clinical practice
Singleplex determinations of allergen-speci c IgE against allergen molecules enable sensitization (i.e., allergic disposition) to be detected or excluded in a targeted manner. e novel opportunities o ered by molecular allergology-increased test sensitivity and superior analytical speci city, marker function for primary sensitizations, and indicator function for serological cross-reactions-improve test characteristics, thereby broadening the opportunities offered hitherto exclusively extract-based diagnostics. us, carefully de ned allergen molecules serve as a useful complement to the reagents available to date, and optimize IgE determinations and the detection of speci c sensitization in the context of allergy diagnosis.
Our additional knowledge on molecular relationships will enable a more comprehensive and specific interpretation of variable IgE repertoires and sensitization patterns on the basis of singleplex determinations and make counseling easier. A prerequisite of this, however, is that the clinical relevance of these ndings continues to be consistently determined based on individual symptoms and clinical reactions in the a ected patient on a case-by-case basis. 
